Multidrug-Resistant Bacteria in the Community

Spellberg, 2011, Combating antimicrobial resistance: policy recommendations to save lives, Clin Infect Dis, 52, S397

Vardakas, 2013, Predictors of mortality in patients with infections due to multi-drug resistant gram negative bacteria: the study, the patient, the bug or the drug?, J Infect, 66, 401

Bodi, 2001, Impact of gram-positive resistance on outcome of nosocomial pneumonia, Crit Care Med, 29, N82, 10.1097/00003246-200104001-00005

Perez, 2013, Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients, Cleve Clin J Med, 80, 225, 10.3949/ccjm.80a.12182

Ena, 1993, The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study, JAMA, 269, 598, 10.1001/jama.1993.03500050076029

Morin, 2001, Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998, J Infect Dis, 184, 1029, 10.1086/323459

Friedman, 2002, Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections, Ann Intern Med, 137, 791, 10.7326/0003-4819-137-10-200211190-00007

American Thoracic Society and Infectious Diseases Society of America, 2005, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST

Safdar, 2002, The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida, Ann Intern Med, 136, 834, 10.7326/0003-4819-136-11-200206040-00013

Van Duin, 2014, Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance, Clin Microbiol Infect, 20, O1117, 10.1111/1469-0691.12714

Kaye, 2005, The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance, Infect Control Hosp Epidemiol, 26, 346, 10.1086/502550

Harris, 2005, Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms, Infect Control Hosp Epidemiol, 26, 342, 10.1086/502549

McKinnell, 2012, Association between vancomycin-resistant enterococci bacteremia and ceftriaxone usage, Infect Control Hosp Epidemiol, 33, 718, 10.1086/666331

Costerton, 1999, Bacterial biofilms: a common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318

Ruimy, 2010, Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans?, J Infect Dis, 202, 924, 10.1086/655901

DeLeo, 2010, Community-associated meticillin-resistant Staphylococcus aureus, Lancet, 375, 1557, 10.1016/S0140-6736(09)61999-1

Witte, 2009, Community-acquired methicillin-resistant Staphylococcus aureus: what do we need to know?, Clin Microbiol Infect, 15, 17, 10.1111/j.1469-0691.2009.03097.x

Saravolatz, 1982, Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks, Ann Intern Med, 97, 325, 10.7326/0003-4819-97-3-325

Thurlow, 2012, Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), FEMS Immunol Med Microbiol, 65, 5, 10.1111/j.1574-695X.2012.00937.x

Alam, 2015, Transmission and microevolution of USA300 MRSA in U.S. households: evidence from whole-genome sequencing, MBio, 6, e00054, 10.1128/mBio.00054-15

Graveland, 2011, Livestock-associated methicillin-resistant Staphylococcus aureus in animals and humans, Int J Med Microbiol, 301, 630, 10.1016/j.ijmm.2011.09.004

Murray, 2000, Vancomycin-resistant enterococcal infections, N Engl J Med, 342, 710, 10.1056/NEJM200003093421007

Coque, 1996, Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States, Antimicrob Agents Chemother, 40, 2605, 10.1128/AAC.40.11.2605

Silverman, 1998, Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci, J Clin Microbiol, 36, 830, 10.1128/JCM.36.3.830-832.1998

Bruinsma, 2003, Antibiotic use and the prevalence of antibiotic resistance in bacteria from healthy volunteers in the Dutch community, Infection, 31, 9, 10.1007/s15010-002-3035-8

Bates, 1997, Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection, J Hosp Infect, 37, 89, 10.1016/S0195-6701(97)90179-1

Klare, 1999, Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry, Microb Drug Resist, 5, 45, 10.1089/mdr.1999.5.45

D'Agata, 2001, Community dissemination of vancomycin-resistant Enterococcus faecium, Am J Infect Control, 29, 316, 10.1067/mic.2001.117448

Poole, 2005, Vancomycin-resistant Enterococcus faecium strains isolated from community wastewater from a semiclosed agri-food system in Texas, Antimicrob Agents Chemother, 49, 4382, 10.1128/AAC.49.10.4382-4385.2005

Omotola, 2013, Risk factors for and epidemiology of community-onset vancomycin-resistant Enterococcus faecalis in southeast Michigan, Am J Infect Control, 41, 1244, 10.1016/j.ajic.2013.05.025

Wolfe, 2014, Prevalence and risk factors for antibiotic-resistant community-associated bloodstream infections, J Infect Public Health, 7, 224, 10.1016/j.jiph.2014.01.001

Foucault, 2010, Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci, Proc Natl Acad Sci U S A, 107, 16964, 10.1073/pnas.1006855107

Johnsen, 2011, Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures, J Antimicrob Chemother, 66, 608, 10.1093/jac/dkq512

Gilmore, 2015, Pheromone killing of multidrug-resistant Enterococcus faecalis V583 by native commensal strains, Proc Natl Acad Sci U S A, 112, 7273, 10.1073/pnas.1500553112

Munoz-Price, 2008, Acinetobacter infection, N Engl J Med, 358, 1271, 10.1056/NEJMra070741

Falagas, 2007, Community-acquired Acinetobacter infections, Eur J Clin Microbiol Infect Dis, 26, 857, 10.1007/s10096-007-0365-6

Eveillard, 2013, Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections, Int J Infect Dis, 17, e802, 10.1016/j.ijid.2013.03.021

Poirel, 2006, Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology, Clin Microbiol Infect, 12, 826, 10.1111/j.1469-0691.2006.01456.x

Sengstock, 2010, Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes, Clin Infect Dis, 50, 1611, 10.1086/652759

Queenan, 2012, Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010, Diagn Microbiol Infect Dis, 73, 267, 10.1016/j.diagmicrobio.2012.04.002

Zeana, 2003, The epidemiology of multidrug-resistant Acinetobacter baumannii: does the community represent a reservoir?, Infect Control Hosp Epidemiol, 24, 275, 10.1086/502209

Davis, 2014, A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols, Chest, 146, 1038, 10.1378/chest.13-3065

Peng, 2012, Acinetobacter baumannii isolates associated with community-acquired pneumonia in West China, Clin Microbiol Infect, 18, E491, 10.1111/1469-0691.12017

Paterson, 2006, The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species, Clin Infect Dis, 43, S43, 10.1086/504476

Hassett, 2009, Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways, Trends Microbiol, 17, 130, 10.1016/j.tim.2008.12.003

O'Malley, 2009, Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist, Respir Care, 54, 641, 10.4187/aarc0446

Rodriguez-Bano, 2010, Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals, Clin Microbiol Infect, 16, 1408, 10.1111/j.1469-0691.2010.03089.x

Anderson, 2014, Bloodstream infections in community hospitals in the 21st century: a multicenter cohort study, PLoS One, 9, e91713, 10.1371/journal.pone.0091713

Hattemer, 2013, Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa, Antimicrob Agents Chemother, 57, 3969, 10.1128/AAC.02467-12

Ulug, 2010, Pyogenic liver abscess caused by community-acquired multidrug resistance Pseudomonas aeruginosa, Braz J Infect Dis, 14, 218, 10.1016/S1413-8670(10)70046-5

Pitout, 2013, Enterobacteriaceae that produce extended-spectrum beta-lactamases and AmpC beta-lactamases in the community: the tip of the iceberg?, Curr Pharm Des, 19, 257, 10.2174/138161213804070348

Doi, 2013, Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States, Clin Infect Dis, 56, 641, 10.1093/cid/cis942

Petty, 2014, Global dissemination of a multidrug resistant Escherichia coli clone, Proc Natl Acad Sci U S A, 111, 5694, 10.1073/pnas.1322678111

Banerjee, 2013, Predictors and molecular epidemiology of community-onset extended-spectrum beta-lactamase-producing Escherichia coli infection in a Midwestern community, Infect Control Hosp Epidemiol, 34, 947, 10.1086/671725

Leistner, 2013, Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. An exploratory case-control study, PLoS One, 8, e74323, 10.1371/journal.pone.0074323

Gopal Rao, 2015, Key demographic characteristics of patients with bacteriuria due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in a multiethnic community, in North West London, Infect Dis (Lond), 47, 719, 10.3109/23744235.2015.1055588

Rogers, 2014, Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries, Antimicrob Agents Chemother, 58, 2126, 10.1128/AAC.02052-13

Ko, 2002, Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns, Emerg Infect Dis, 8, 160, 10.3201/eid0802.010025

Li, 2014, Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China, Clin Infect Dis, 58, 225, 10.1093/cid/cit675

Tamma, 2015, Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia, Clin Infect Dis, 60, 1319

Rodriguez-Bano, 2012, β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts, Clin Infect Dis, 54, 167, 10.1093/cid/cir790

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed July 10, 2015.

Yigit, 2001, Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae, Antimicrob Agents Chemother, 45, 1151, 10.1128/AAC.45.4.1151-1161.2001

Nordmann, 2009, The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria, Lancet Infect Dis, 9, 228, 10.1016/S1473-3099(09)70054-4

Schwaber, 2008, Carbapenem-resistant Enterobacteriaceae: a potential threat, JAMA, 300, 2911, 10.1001/jama.2008.896

Hirsch, 2010, Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection, J Antimicrob Chemother, 65, 1119, 10.1093/jac/dkq108

Neuner, 2011, Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections, Diagn Microbiol Infect Dis, 69, 357, 10.1016/j.diagmicrobio.2010.10.013

van Duin, 2013, Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes, Diagn Microbiol Infect Dis, 75, 115, 10.1016/j.diagmicrobio.2012.11.009

Epstein, 2014, New Delhi metallo-beta-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes, JAMA, 312, 1447, 10.1001/jama.2014.12720

Khajuria, 2014, Emergence of Escherichia coli, co-producing NDM-1 and OXA-48 carbapenemases, in urinary isolates, at a tertiary care centre at Central India, J Clin Diagn Res, 8, DC01

Bhargava, 2014, Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilities, Infect Control Hosp Epidemiol, 35, 398, 10.1086/675614

Walsh, 2011, Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study, Lancet Infect Dis, 11, 355, 10.1016/S1473-3099(11)70059-7

Wang, 2012, Identification of New Delhi metallo-beta-lactamase 1 in Acinetobacter lwoffii of food animal origin, PLoS One, 7, e37152, 10.1371/journal.pone.0037152

Pannaraj, 2015, Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States, Pediatr Infect Dis J, 34, 11, 10.1097/INF.0000000000000471

Hussain, 2014, Genotypic and phenotypic profiles of Escherichia coli isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal non-ST131 lineages from India, Antimicrob Agents Chemother, 58, 7240, 10.1128/AAC.03320-14

Peirano, 2011, Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131, Antimicrob Agents Chemother, 55, 2986, 10.1128/AAC.01763-10

Hawkey, 2009, The changing epidemiology of resistance, J Antimicrob Chemother, 64, i3, 10.1093/jac/dkp256

Marathe, 2013, A treatment plant receiving waste water from multiple bulk drug manufacturers is a reservoir for highly multi-drug resistant integron-bearing bacteria, PLoS One, 8, e77310, 10.1371/journal.pone.0077310

Forsberg, 2012, The shared antibiotic resistome of soil bacteria and human pathogens, Science, 337, 1107, 10.1126/science.1220761

Wagner, 2014, Antimicrobial stewardship programs in inpatient hospital settings: a systematic review, Infect Control Hosp Epidemiol, 35, 1209, 10.1086/678057

Gangat, 2015, Antibiotic stewardship: a focus on ambulatory care, S D Med, Spec No, 44

Vinski, 2012, Impact of isolation on hospital consumer assessment of healthcare providers and systems scores: is isolation isolating?, Infect Control Hosp Epidemiol, 33, 513, 10.1086/665314

Coates, 2009, Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects, J Antimicrob Chemother, 64, 9, 10.1093/jac/dkp159

Chen, 2013, Staphylococcus aureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections, Clin Orthop Relat Res, 471, 2383, 10.1007/s11999-013-2875-0